Top news of the week: 20.10.2020.

#genetherapy #3D #biopharma #NobelPrize2020 #UMassMedNews #bioprocessing #Bioprinting #biotechnology #biospace #lifesciences

Companies And Industries

On Oct 19, 2020
@FierceBiotech shared
M&A activity still looks fairly lively in 2020 despite a somewhat subdued start as the industry adapted to the looming coronavirus pandemic. https://t.co/u7ZpDjIr71
Open

The top 10 takeover targets in biopharma

The top 10 takeover targets in biopharma

Most if not all large-cap pharma and biotech companies are still in need of business development as they work to rebalance their operations. Cancer, rare disease, and to a lesser extent ...

On Oct 19, 2020
@GENbio shared
Rentschler Biopharma and [email protected]_bio Ink Leap-In Transposase Licensing Deal. Read more: https://t.co/E860euZYTp #biopharma #bioprocessing https://t.co/FHJOVqy4rp
Open

Rentschler Biopharma and ATUM Ink Leap-In Transposase Licensing Deal

Rentschler Biopharma and ATUM Ink Leap-In Transposase Licensing Deal

Rentschler plans to integrate the technology into its in-house process with what it calls a fast, cost-effective, and stable platform.

On Oct 16, 2020
@GENbio shared
[email protected] raises $30 M in Financing. The new funding will help take their manufacturing platform to the market that delivers solutions to address the clinical and commercial manufacturing needs of cell and #genetherapy developers. Learn more: https://t.co/3KDStJHa7A https://t.co/FryA7W3zq3
Open

Ori Biotech Raises $30 Million in Financing

Ori Biotech Raises $30 Million in Financing

 Funds will be used to advance innovation in cell and gene therapy manufacturing.

On Oct 16, 2020
@CellCultureDish shared
See what biotech news you missed this week in the Dish's weekly wrap up - https://t.co/Ae52BMIY95
Open

The Dish’s Weekly Biotechnology News Wrap Up – October 16, 2020

The Dish’s Weekly Biotechnology News Wrap Up – October 16, 2020

0 0 0 Total0 This week’s headlines include: U.S. government signs deal to make more COVID-19 vaccine components, Eli Lilly pauses study of COVID-19 treatment over safety concerns, Pfizer to ...

On Oct 18, 2020
@NatureBiotech shared
RT @UMassMedical: Guangping Gao, PhD, & #NobelPrize2020 winner Jennifer Doudna are both on @NatureBiotech's list of top translational biotech researchers for 2019. The #genetherapy pioneer & director of @UMMSGeneTherapy was on the 2018 list too. https://t.co/DQLXMsOuro @nresearchnews #UMassMedNews
Open

Guangping Gao makes list of Nature Biotechnology Top 20 translational researchers

Guangping Gao makes list of Nature Biotechnology Top 20 translational researchers

An influential scientific journal’s list of top translational biotech researchers for 2019 includes Guangping Gao, PhD. Rankings are based on total patents for the year, among other ...

On Oct 16, 2020
@biospace shared
Manufacturing a Personalized Cellular Universe: 3D Bioprinting in the Biotech Industry #biospace #lifesciences #biotechnology #pharmaceuticals #3D #Bioprinting https://t.co/LHXSLKg1BA
Open

Manufacturing a Personalized Cellular Universe: 3D Bioprinting in the Biotech Industry

Manufacturing a Personalized Cellular Universe: 3D Bioprinting in the Biotech Industry

By using naturally-derived scaffolds, human cells and other biocompatible materials, 3D bioprinting has ushered in opportunities for researchers to design, print and optimize patient ...

On Oct 19, 2020
@matthewherper shared
Wait it's a cancer drug? @endpts makes a curious find on Calico: https://t.co/5gUetAPsAV
Open

Super-secretive anti-aging biotech Calico tees up the first visible clinical trial of an experimental drug. And it’s for cancer?

Super-secretive anti-aging biotech Calico tees up the first visible clinical trial of an experimental drug. And it’s for cancer?

Over the past 7 years, Calico has been so much more than your average, run-of-the-mill secretive biotech players. It’s a riddle, wrapped in a mystery, inside an enigma, to repurpose an old ...

On Oct 19, 2020
@BioWorld shared
SPACs are hot this year, offering alternative route to public market https://t.co/kIOzinvqhe
Open

SPACs are hot this year, offering alternative route to public market

SPACs are hot this year, offering alternative route to public market

Even though the appetite for biopharma IPOs this year has been voracious with no signs of a slowdown anytime soon, companies also have a potentially faster route to the public market using ...